Expozyme Ltd Filleted Accounts Cover
Expozyme Ltd
Company No. 07128474
Information for Filing with The Registrar
31 January 2026
Expozyme Ltd Directors Report Registrar
The Director presents his report and the accounts for the year ended 31 January 2026.
Principal activities
The principal activity of the company during the year under review was commission income.
Director
The Director who served at any time during the year was as follows:
H. Arzoumanian
The above report has been prepared in accordance with the provisions applicable to companies subject to the small companies regime as set out in Part 15 of the Companies Act 2006.
Signed on behalf of the board
H. Arzoumanian
Director
31 October 2026
Expozyme Ltd Balance Sheet Registrar
at
31 January 2026
Company No.
07128474
Notes
2026
2025
£
£
Current assets
Debtors
25,01625,000
Cash at bank and in hand
134,847182,058
159,863207,058
Creditors: Amount falling due within one year
(542)
(2,481)
Net current assets
159,321204,577
Total assets less current liabilities
159,321204,577
Net assets
159,321204,577
Capital and reserves
Called up share capital
100100
Profit and loss account
5
159,221204,477
Total equity
159,321204,577
These accounts have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime of the Companies Act 2006.
For the year ended 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
All the members have consented to the preparation of abridged financial statements for the year ended 31 January 2026 in accordance with the Companies Act 2006.
As permitted by section 444 (5A)of the Companies Act 2006 the directors have not delivered to the Registrar a copy of the company's profit and loss account.
Approved by the board on 31 October 2026 and signed on its behalf by:
H. Arzoumanian
Director
31 October 2026
Expozyme Ltd Notes to the Accounts Registrar
for the year ended 31 January 2026
1
General information
Expozyme Ltd is a private company limited by shares and incorporated in England and Wales.
Its registered number is: 07128474
Its registered office is:
4 Whitchurch Parade,
Whitchurch Lane
Edgware
Middlesex
HA8 6LR
The abridged accounts have been prepared in accordance with FRS 102 Section 1A - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006, including the provisions permitting an abridged profit and loss account and balance sheet to be prepared.
2
Accounting policies
Turnover
Turnover is measured at the fair value of the consideration received or receivable. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

Revenue from the sale of goods is recognised when all the following conditions are satisfied:
• the Company has transferred to the buyer the significant risks and rewards of ownership of the
goods;
• the Company retains neither continuing managerial involvement to the degree usually associated
with ownership nor effective control over the goods sold;
• the amount of revenue can be measured reliably;
• it is probable that the economic benefits associated with the transaction will flow to the Company;
and
• the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Specifically, revenue from the sale of goods is recognised when goods are delivered and legal title is passed.
3
Employees
2026
2025
Number
Number
The average monthly number of employees (including directors) during the year was:
11
4
Share Capital
100 Ordinary shares of £1 each
5
Reserves
Profit and loss account - includes all current and prior period retained profits and losses.
6
Dividends
2026
2025
£
£
Dividends for the period:
Dividends paid in the period
37,500
38,000
37,500
38,000
Dividends by type:
Equity dividends
37,50038,000
37,500
38,000
Expozyme Ltd0712847431 January 202601 February 2025false31 October 2026BTCSoftware AP Solution 2026 14.1.1914.1.19true071284742025-02-012026-01-31071284742026-01-31071284742025-01-3107128474core:WithinOneYear2026-01-3107128474core:WithinOneYear2025-01-3107128474core:ShareCapital2026-01-3107128474core:ShareCapital2025-01-3107128474core:RetainedEarningsAccumulatedLosses2026-01-3107128474core:RetainedEarningsAccumulatedLosses2025-01-3107128474countries:UnitedKingdom2025-02-012026-01-3107128474bus:RegisteredOffice2025-02-012026-01-31071284742024-02-012025-01-3107128474core:RetainedEarningsAccumulatedLosses2025-02-012026-01-3107128474bus:AllOrdinaryShares2025-02-012026-01-31071284742025-02-0107128474bus:SmallEntities2025-02-012026-01-3107128474bus:AbridgedAccounts2025-02-012026-01-3107128474bus:AuditExempt-NoAccountantsReport2025-02-012026-01-3107128474bus:Director12025-02-012026-01-3107128474bus:PrivateLimitedCompanyLtd2025-02-012026-01-31iso4217:GBPxbrli:pure